drugset / Trial / NCT00964106

Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation

NCT00964106

Phase 1 Completed 87 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to identify and validate a probe cocktail for use in future drug-drug interaction studies. Cytochrome P450 enzymes and transport proteins play important roles in the disposition of drugs. Changes in the activity of these pathways can be assessed using probe drugs selected on the basis of their metabolic or transport pathway. This will be a two part study with the same subjects participating in both parts to decrease variability in data. The purpose of Part 1 is to identify a set of probe drugs ('cocktail') which do not interact with one another; groups of healthy volunteers will receive 7 probe drugs individually and as a combination of the 7 drugs given together as a cocktail. Part 2 will assess the performance of the probe cocktail using three known inhibitors (validation). The inhibitors plus probe cocktail will evaluate the ability of the newly established cocktail to accurately quantify metabolizing enzyme or transporter inhibition, representing a fundamental advance in probe cocktail validation and utility for drug development.

Timeline

Start
2009-08-26
Primary completion
2011-08-29
Completion
2011-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule 100 mg
Subject Dextromethorphan Unknown 30 mg
Subject Fluconazole Small molecule 200 mg
Subject Fluconazole Small molecule 400 mg
Subject Flurbiprofen Small molecule 40 mg
Subject Ketoconazole Small molecule 400 mg
Subject Midazolam Small molecule 1 mg
Subject Midazolam Small molecule 3 mg
Subject Omeprazole Other / unclassified 20 mg
Subject Rifampin Small molecule 600 mg
Subject Rosiglitazone Small molecule 4 mg
Subject Rosiglitazone Small molecule 15 mg
Subject Rosuvastatin Small molecule 10 mg

Indications

No indication recorded.